Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06441968
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-05-31
Brief Title:
Safety and Immunogenicity Trial of MPVS-2P SARS-CoV-2 Vaccine in Adults
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
A Phase 1 Open-Label Safety and Immunogenicity Trial of MPVS-2P a Next Generation SARS-CoV-2 Booster Vaccine in Previously Vaccinated Adults
Status:
RECRUITING
Status Verified Date:
2024-05-29
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A clinical trial to evaluate the safety reactogenicity and immunogenicity of MPVS-2P administered intranasally to adults who have previously received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine The primary objective is to evaluate the safety and reactogenicity of a single dose of MPVS-2P in previously vaccinated healthy adults
Detailed Description:
A phase I clinical trial to evaluate the safety reactogenicity and immunogenicity of MPVS-2P administered intranasally to adults who have previously received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine The study is designed as a non-randomized open-label dose-escalation clinical trial in non-pregnant adult participants 18-64 years of age with a goal of 30 percent or more 50 years of age with or without prior SARS-CoV-2 infection who are in good health and meet all other eligibility criteria For the evaluation of three doses of MPVS-2P vaccine a sample size of 60 participants is anticipated
To evaluate for early safety signals vaccination will proceed in a staged fashion For Cohort 1 three sentinel participants under 50 years of age will be enrolled over at least 2 days A safety review of clinical data and virologic shedding data through at least Day 8 will be conducted by the Safety Review Committee SRC prior to enrollment of the remainder of the cohort Once Cohort 1 is fully enrolled progression to Cohort 2 will be based on evaluation of halting rules and cumulative clinical safety and virologic shedding data from Cohort 1 through at least Day 8 by the SRC
Cohort 2 and 3 enrollment and safety oversight will proceed in the same fashion as Cohort 1 At the discretion of the SRC additional participants in the cohort may be designated sentinels for any cohort If halting rules are met the study will be paused for the SRC safety data review
The primary objective is to evaluate the safety and reactogenicity of a single dose of MPVS-2P in previously vaccinated healthy adults The secondary objectives are 1 To evaluate the systemic anti-Spike humoral immune responses after vaccination 2 To evaluate nasal mucosal IgA and IgG responses after vaccination 3 To assess the duration and magnitude of viral vector vaccine shedding 4 To assess the immune response towards the vector
To evaluate for early safety signals vaccination will proceed in a staged fashion For Cohort 1 three sentinel participants under 50 years of age will be enrolled over at least 2 days A safety review of clinical data and virologic shedding data through at least Day 8 will be conducted by the Safety Review Committee SRC prior to enrollment of the remainder of the cohort Once Cohort 1 is fully enrolled progression to Cohort 2 will be based on evaluation of halting rules and cumulative clinical safety and virologic shedding data from Cohort 1 through at least Day 8 by the SRC
Cohort 2 and 3 enrollment and safety oversight will proceed in the same fashion as Cohort 1 At the discretion of the SRC additional participants in the cohort may be designated sentinels for any cohort If halting rules are met the study will be paused for the SRC safety data review
The primary objective is to evaluate the safety and reactogenicity of a single dose of MPVS-2P in previously vaccinated healthy adults The secondary objectives are 1 To evaluate the systemic anti-Spike humoral immune responses after vaccination 2 To evaluate nasal mucosal IgA and IgG responses after vaccination 3 To assess the duration and magnitude of viral vector vaccine shedding 4 To assess the immune response towards the vector
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None